Werewolf Therapeutics (HOWL)
(Delayed Data from NSDQ)
$1.18 USD
-0.01 (-0.84%)
Updated Aug 7, 2025 04:00 PM ET
After-Market: $1.18 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Werewolf Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
HOWL 1.18 -0.01(-0.84%)
Will HOWL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HOWL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HOWL
CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
HOWL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates
Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline
Pacira (PCRX) Tops Q4 Earnings Estimates
Other News for HOWL
Werewolf Therapeutics Adopts New Bylaws and Elects Directors
Werewolf Therapeutics (HOWL) Price Target Lowered by BofA, Buy Rating Maintained | HOWL Stock News
Werewolf Therapeutics price target lowered to $9 from $10 at BofA
Werewolf Therapeutics price target lowered by $1 at BofA, here's why
Bank of America Securities Remains a Buy on Werewolf Therapeutics (HOWL)